Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AXXA should have used the $1.5M on a share buyback instead of the memorabilia! They could have bought back almost 215,000,000 shares at today's price. NEWS about that probably would have had a much greater positive effect than the memorabilia NEWS they put out!
Excellent COVID Update: Tech Launch Arizona, the office of UArizona that commercializes inventions stemming from research, has been working with pharmaceutical company Sunshine Biopharma Inc. (NASDAQ: “SBFM”) to develop pathways to bring the invention to the public. The license grants Sunshine Biopharma worldwide rights for the University of Arizona and University of Illinois Chicago patent rights pertaining to PLpro protease inhibitors of SARS-CoV-2 developed by the researchers.
Let's get it back to $10/PPS first!
Excellent update on SBFM COVID treatment progress. Looks like Greg Thatcher and colleagues are planning to take this all the way to the FDA!
PS: I know a couple people who recently needed COVID treatment so looks like there is and will be a market for some time to come in the US and beyond.
No way $1.00 unless AXXA buys back 75% of the float. Even then not sure it could make it past $.40.
How do you see $1.00?
I was thinking the company (CCAJ) should cancel the proposed RS and buy back something like 500 million shares (about $750,000 at today's market prices) over the next several weeks and then use those shares for the merger/acquisitions. I think CCAJ has some money to do this!
I'm sure the price would go up if they were to do this so they wouldn't get 500 million for $750,000 and would have to put out more cash for that amount of shares.
I know this is a pipedream, but that was my thinking on the current situation.
Looks like they updated to a new website recently, but have the same info.
This new site looks better, but not sure if this new site means much in terms of what is happening behind the scenes. https://coastalcapitalacquisitioncorp.com/acquisitions/
The old one is still there (as of today at least):
https://coastalcapitalac.com/acquisitions
It is on the CCAJ website as an "Identified Acquisition." See link:
https://coastalcapitalac.com/acquisitions
More details please....who owns it if AXXA don't?
CCAJ should cancel the RS and buyback half the float! That should make the price go up significantly. I remember when some thought CCAJ would hit $0.20!
A 1:10 RS at .20 makes a lot more sense to get up to $2.00.
I recall a COVID research article from the UGA study.
As for the way forward for SBFM's cancer compound, I do see progress in the recently signed cancer research agreement between SBFM and JGH. In 2022 SBFM said this was the next step for IND-enabling studies and now they have executed a definitive agreement (see below).
Item 1.01. Entry into a Material Definitive Agreement.
On February 7, 2023, Sunshine Biopharma, Inc. (the “Company”) received a duly executed research agreement (the “Research Agreement”) with Sir
Mortimer B. Davis Jewish General Hospital, a McGill University Health Center hospital located in Montreal, Quebec, Canada (“JGH”) in connection with
the Company’s Adva-27a anticancer compound. The research effort will be focused on advancing the development of the Company’s Adva-27a anticancer
compound through the IND-enabling studies. In the event that the research results are conclusive and the Company determines that it wishes to conduct a
Phase I clinical trial on the Adva-27a molecule, the parties agree to negotiate an agreement to determine the responsibilities and obligations of the parties
for such Phase I clinical trial.
Let's see where the 4Q results and NEWS take this soon! We surely know where the December NEWS took this.
I like the word "soon" if it comes with a timeframe. Is it days, weeks or months?
Next, I think we'll get an update from SBFM on the following (perhaps next month):
"The Company’s collaboration partner will prepare two LNP formulations (K1.1a and K1.1b) of Sunshine Biopharma’s in-house developed antineoplastic mRNA, K1.1. Sunshine Biopharma had previously shown that its K1.1 mRNA is capable of destroying cancer cells in vitro, including multidrug resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2)."
Excellent progress! Last year SBFM said this would be the next step and here it comes in 2023. IND-enabling studies and clinical trials for Adva-27a.
"We look forward to continuing the project with the Hospital past the IND-enabling studies and through the clinical trials to bring a new treatment for cancer sufferers around the world," he added.
If don't recall how much they spent on NORA so not sure how much they have left in the bank. Now they have dedicated $2M to the current buyback so I figured they could spend a bit more on that to help the share price for now and until they have a PR on a breakthrough based on something they are doing. Most doubt there is a breakthrough coming, but that is what I'm looking forward to in the next 4-6 months. By June we should know one way or the other!
Another share buyback. SBFM should buyback half the float which would be another $9M at current prices. If they get the OS down below 10M, get the LNPs working, and start clinical trials in the MAR-APR 2023 timeframe, that should be the needed catalysts and move this back to $2-4/share!
Is this the LNP Company in Vancouver, BC, Canada that SBFM is working with?
https://acuitastx.com
Looks like they are working with Pfizer: https://acuitastx.com/wp-content/uploads/2022/01/Acuitas-Pfizer-Agreement-Release.pdf
More COVID ahead (see article below). SBFM needs to pick up the pace in 2023 to develop their COVID pill!
https://www.cnn.com/2023/01/04/health/public-health-concerned-xbb/index.html
Happy 2nd AXXA Trading Day of 2023! Day 1 was definitely not a good start to the New Year. Looking forward to some unexpected positive excitement in the coming days/weeks/months!
Happy 2nd SBFM Trading Day of 2023! Day 1 was definitely a good start to the New Year. Looking forward to some unexpected positive excitement in the coming days/weeks/months!
Happy 2nd CCAJ Trading Day of 2023! Day 1 was definitely a quiet start to the New Year. Looking forward to some unexpected positive excitement in the coming days/weeks/months!
Happy 1st AXXA Trading Day of 2023. Looking for better days, weeks and months ahead!
Happy 1st SBFM Trading Day of 2023. Looking for better days, weeks and months ahead!
Happy 1st CCAJ Trading Day of 2023. Looking for better days, weeks and months ahead!
Interesting rumor, but I'm not sure we have heard the last of the PLpro anti-Coronavirus mice trials from the University of Arizona or the upcoming K1.1-LNP xenograft mice in vivo cancer trials in March 2023.
Nonetheless, the RS has clearly failed. Had the PPS stayed above $4 (or even $2) in 2022 I might have thought otherwise. If it gets back to $2-4+ in 2023 then I'll have different thoughts on this!
Who knows what type of PR will come out, but it will likely be related to progress on the SBFM topics below:
July 2022: expanded collaboration with the University of Arizona to accelerate the development of our novel PLpro inhibitors for our anti-Coronavirus treatment program.
October 2022: acquired Canadian generic pharmaceuticals company, Nora Pharma Inc., with sales of approximately $14 million. Sunshine Biopharma now has over 50 generic prescription drugs on the market in Canada with plans to grow further throughout North America and potentially other markets around the world.
November 2022: vigorously pushed forward with our oncology K1.1 mRNA development program by entering into a key collaboration arrangement with a leading lipid nano-particle (LNP) formulation company in North America. Beginning in March, 2023, our partner generated K1.1-LNP formulations will be used to conduct in vivo studies on xenograft mice expressing the in vitro tested human cancers as well as liver cancer. Should these mice studies prove successful, the Company can advance relatively rapidly to conducting human trials.
2023: objectives going forward will be focused on achieving profitability and investing in our proprietary drug development program.
Hoping that is the case for 2023! I'm just highlighting the 52-week range from $.09 to $.008 and where it ended yesterday. Good companies should increase value if I'm not mistaken!
Our bags may be full of coal now, but 2023 may be the year that SBFM turns it into gold. Check back in 6 months and we'll chat again.
0 trading days left until 2023 and the end of 2022 was not good for AXXA shareholders (except today's gain). Let's see if the management can come into 2023 with a new strategy that rewards vs. punishes existing shareholders.
0 trading days left until 2023 and the end of 2022 was not good for SBFM shareholders. Let's see if the management can come into 2023 with a new strategy that rewards vs. punishes existing shareholders.
0 trading days left until 2023 and the end of 2022 was not good for CCAJ shareholders. Let's see if the management can come into 2023 with a new strategy that rewards vs. punishes existing shareholders.
I keep seeing FDA Acceptance of IND Application PRs for biopharma companies so perhaps that will be the excitement in 2023 for SBFM. Stock prices seem to go up between 100-300% for those announcements. Time to get the ball rolling!
Below is one example:
https://ih.advfn.com/stock-market/NASDAQ/hoth-therapeutics-HOTH/stock-news/89873816/hoth-therapeutics-announces-fda-acceptance-of-ind
2 more trading days until AXXA starts a new year of trading in 2023! Looking forward to some new found excitement and momentum throughout the new year.
2 more trading days until SBFM starts a new year of trading in 2023! Looking forward to some new found excitement and momentum throughout the new year.
2 more trading days until CCAJ starts a new year of trading in 2023! Looking forward to some new found excitement and momentum throughout the new year.
And to All Good Luck in 2023!
4 trading days left in 2022. Unfortunately 2022 did not go as expected. Not expecting much next week, but hopefully AXXA can generate some unexpected excitement early in 2023.
4 trading days left in 2022. Unfortunately 2022 did not go as expected. Not expecting much next week, but hopefully SBFM can generate some unexpected excitement early in 2023.
4 trading days left in 2022. Unfortunately 2022 did not go as expected. Not expecting much next week, but hopefully CCAJ can generate some unexpected excitement early in 2023.